Medroxyprogesterone Injection Recalled Due to Sterility Concerns
Clinical Specialties Compounding Pharmacy is recalling Medroxyprogesterone 50 mg/ml injections due to FDA inspection findings regarding quality control and sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score per the rubric, particularly given the risk of infection associated with lack of sterility assurance in injectable drugs.
Plain-English summary
Clinical Specialties Compounding Pharmacy is recalling Medroxyprogesterone 50 mg/ml injections. The recall was initiated following FDA inspection findings that raised concerns regarding the quality control processes used to ensure the sterility of the product.
The affected product is identified by Lot number CABDABAC:01 with an expiration date of 5/2/2013. The product was distributed in Florida, Georgia, and South Carolina.
Consumers and healthcare providers should stop using the recalled product and contact the pharmacy or their healthcare provider for further instructions.
The recalled product
- Product
- Medroxyprogesterone 50 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907
- Manufacturer
- Clinical Specialties Compounding Pharmacy
- Category
- Drug — Injectable
- Affected units
- 2
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot number CABDABAC:01
- Exp date: 5/2/2013.
Distribution
Part of a larger recall action
This product is one of 49 recalled by Clinical Specialties Compounding Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 49 products in this recall →Related recalls
Same manufacturer · Clinical Specialties Compounding Pharmacy
See all →- SevereAvastin Syringes Recalled for Sterility Concerns and Eye Infection Reports
FDA (Drugs) · 2013-09-04
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 250 mg-lidocaine 5 mg/ml
FDA (Drugs) · 2013-07-10
- SevereEstradiol Cypionate Injection Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 200 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 100 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- HighInjectable hormone medication recalled for sterility assurance failure
FDA (Drugs) · 2022-11-09
- SevereOlympia Pharmacy Recalls Medroxyprogesterone Injection Due to Sterility Concerns
FDA (Drugs) · 2013-07-17
- SevereGreen Valley Drugs Recalls Medroxyprogesterone Acetate Injection for Sterility Concerns
FDA (Drugs) · 2013-05-22
- SevereUS Compounding Recalls Medroxyprogesterone/Lidocaine Vials Due to Sterility Concerns
FDA (Drugs) · 2015-11-25
- SevereProgesterone Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2015-09-23
- SevereMedroxyprogesterone Acetate Suspension Recalled for Sterility Concerns
FDA (Drugs) · 2021-11-17